Finerenone in Heart Failure with Mildly Reduced or Preserved Ejection Fraction
Open accessThe DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Steroidal mineralocorticoid receptor antagonists reduce morbidity and mortality among patients with heart failure and reduced ejection fraction, but their efficacy in those with heart failure and mildly reduced or preserved ejection fraction has not been established. Data regarding the efficacy and safety of the nonsteroidal mineralocorticoid receptor antagonist finerenone in patients with heart failure and mildly reduced or preserved ejection fraction are needed. METHODS: In this international, double-blind trial, we randomly assigned patients with heart failure and a left ventricular ejection fraction of 40% or greater, in a 1:1 ratio, to receive finerenone (at a maximum dose of 20 mg or 40 mg once daily) or matching placebo, in addition to usual therapy. The primary outcome was a composite of total worsening heart failure events (with an event defined as a first or recurrent unplanned hospitalization or urgent visit for heart failure) and death from cardiovascular causes. The components of the primary outcome and safety were also assessed. RESULTS: Over a median follow-up of 32 months, 1083 primary-outcome events occurred in 624 of 3003 patients in the finerenone group, and 1283 primary-outcome events occurred in 719 of 2998 patients in the placebo group (rate ratio, 0.84; 95% confidence interval [CI], 0.74 to 0.95; P = 0.007). The total number of worsening heart failure events was 842 in the finerenone group and 1024 in the placebo group (rate ratio, 0.82; 95% CI, 0.71 to 0.94; P = 0.006). The percentage of patients who died from cardiovascular causes was 8.1% and 8.7%, respectively (hazard ratio, 0.93; 95% CI, 0.78 to 1.11). Finerenone was associated with an increased risk of hyperkalemia and a reduced risk of hypokalemia. CONCLUSIONS: In patients with heart failure and mildly reduced or preserved ejection fraction, finerenone resulted in a significantly lower rate of a composite of total worsening heart failure events and death from cardiovascular causes than placebo. (Funded by Bayer; FINEARTS-HF ClinicalTrials.gov number, NCT04435626.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Over the past decade, the use of medications that have been demonstrated to be effective in patients with HF with reduced ejection fraction (angiotensin receptor neprilysin inhibitors, mineralocorticoid receptor antagonists, and sodium-glucose cotransporter 2 [SGLT2] inhibitors) has been evaluated in large-scale trials in patients with HF and mildly reduced ejection fraction and patients with HFpE”
From Effects of Tirzepatide on the Clinical Trajectory of Patients With Heart Failure, Preserved Ejection Fraction, and Obesity (2025) · cites this paper as [6]
The cited source says what the claim attributes to it.
In the citing paper
“This level was significantly lower than that in the STEP-HFpEF program (median, ≈470 pg/mL)36 and substantially lower than in other large-scale outcome trials in HFpEF (median 900–1400 pg/mL).3–6”
From Effects of Tirzepatide on the Clinical Trajectory of Patients With Heart Failure, Preserved Ejection Fraction, and Obesity (2025) · cites this paper as [6]
The cited source says what the claim attributes to it.
In the citing paper
“Of the enrolled participants, 41% had type 2 diabetes.”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2026 (2026) · cites this paper as [303]
The cited source says what the claim attributes to it.
In the citing paper
“The selective nonsteroidal MRA finerenone was examined in the Study to Evaluate the Efficacy (Effect on Disease) and Safety of Finerenone in Participants With Heart Failure and Left Ventricular Ejection Fraction (Proportion of Blood Expelled Per Heart Stroke) Greater or Equal to 40% (FINEARTS-HF) trial of people with symptomatic HFpEF (ejection fraction ≥40%) and was found to reduce the risk of”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2026 (2026) · cites this paper as [303]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart Failure
Pitt, B., Zannad, F., Remme, W. J., Cody, R., Castaigne, A., Perez, A., Palensky, J., & Wittes, J. (1999) · New England Journal of Medicine · doi:10.1056/nejm199909023411001 · Cited by 9,214
Self-citationPitt, B., Remme, W., Zannad, F., Neaton, J., Martinez, F., Roniker, B., Bittman, R., Hurley, S., Kleiman, J., & Gatlin, M. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa030207 · Cited by 4,941
Self-citationEmpagliflozin in heart failure with a preserved ejection fraction
Anker, S. D., Butler, J., Filippatos, G., Ferreira, J. P., Bocchi, E., Böhm, M., Brunner–La Rocca, H.-P., Choi, D.-J., Chopra, V., Chuquiure-Valenzuela, E., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2107038 · Cited by 4,874
Self-citationEplerenone in patients with systolic heart failure and mild symptoms
Zannad, F., McMurray, J. J. V., Krum, H., van Veldhuisen, D. J., Swedberg, K., Shi, H., Vincent, J., Pocock, S. J., & Pitt, B. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1009492 · Cited by 3,111
Self-citationEffect of finerenone on chronic kidney disease outcomes in type 2 diabetes
Bakris, G. L., Agarwal, R., Anker, S. D., Pitt, B., Ruilope, L. M., Rossing, P., Kolkhof, P., Nowack, C., Schloemer, P., Joseph, A., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2025845 · Cited by 2,935
Self-citationDapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction
Solomon, S. D., McMurray, J. J. V., Claggett, B., de Boer, R. A., DeMets, D., Hernandez, A. F., Inzucchi, S. E., Kosiborod, M. N., Lam, C. S. P., Martinez, F., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2206286 · Cited by 2,884
Self-citationSpironolactone for heart failure with preserved ejection fraction
Pitt, B., Pfeffer, M. A., Assmann, S. F., Boineau, R., Anand, I. S., Claggett, B., Clausell, N., Desai, A. S., Diaz, R., Fleg, J. L., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1313731 · Cited by 2,809
Self-citationAngiotensin–Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction
Solomon, S. D., McMurray, J. J. V., Anand, I. S., Ge, J., Lam, C. S. P., Maggioni, A. P., Martinez, F., Packer, M., Pfeffer, M. A., Pieske, B., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1908655 · Cited by 2,430
Self-citationSotagliflozin in patients with diabetes and recent worsening heart failure
Bhatt, D. L., Szarek, M., Steg, P. G., Cannon, C. P., Leiter, L. A., McGuire, D. K., Lewis, J. B., Riddle, M. C., Voors, A. A., Metra, M., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2030183 · Cited by 1,868
Self-citationCardiovascular events with finerenone in kidney disease and type 2 diabetes
Pitt, B., Filippatos, G., Agarwal, R., Anker, S. D., Bakris, G. L., Rossing, P., Joseph, A., Kolkhof, P., Nowack, C., Schloemer, P., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2110956 · Cited by 1,814
Self-citation
Cited by
Items 201–300 of 892
Bozkurt, B., Januzzi, J. L., & Bansal, S. (2025) · Reviews in Cardiovascular Medicine · doi:10.31083/rcm38690 · Cited by 8
“Efficacy outcomes were not modified by baseline disease characteristics, including eGFR category, urine albumin-to-creatinine ratio (UACR) category, presence of diabetes, and body mass index [56].”
InfluentialEffect of Finerenone on Morbidity and Mortality in CKD
Ostrominski, J. W., Filippatos, G. S., Claggett, B. L., Miao, Z. M., Desai, A. S., Jhund, P. S., Henderson, A. D., Rohwedder, K., BRINKER, M. D., Scalise, A. V., et al. (2025) · Journal of the American Society of Nephrology · doi:10.1681/asn.0000000823 · Cited by 11
“13 Designed to detect treatment effects on kidney events, the FIDELIO-DKD trial included persons with type 2 diabetes and CKD with predominantly very high levels of albuminuria.”
Self-citationWu, J., Pei, Y.-B., Wu, J., & Huang, Y. (2025) · BMC Cardiovascular Disorders · doi:10.1186/s12872-025-05098-5 · Cited by 9
“o Phenotype comparisons (HFrEF vs. HFpEF) were unfeasible due to missing HFrEF data.”
Ferreira, J. P., Vaduganathan, M., Claggett, B. L., Kulac, I. J., Ostrominski, J. W., Desai, A. S., Jhund, P. S., Lam, C. S. P., Senni, M., Shah, S. J., et al. (2025) · European Journal of Heart Failure · doi:10.1002/ejhf.70052 · Cited by 6
Self-citationGrilo, R. M., & Falcão, L. M. (2025) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2025.10.013 · Cited by 9
Finerenone Versus Spironolactone for Heart Failure with Preserved Ejection Fraction
Habib, E., Ibrahim, R., Pham, H. N., Abdelnabi, M. H., Kanaan, C. N., Eldeib, A., Augusto, S. N., Ayoub, C., Tang, W. H. W., & Arsanjani, R. (2025) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-025-07822-x · Cited by 6
“Finerenone binds selectively with high affinity to the mineralocorticoid receptor while exerting minimal off-target activity on steroid hormone receptors [2 ].”
InfluentialBorlaug, B. A., Chirinos, J. A., Lewis, G. D., Redfield, M. M., Bertoni, A. G., Cadeiras, M., Chiamvimonvat, N., Desai, A. S., Givertz, M. M., Kass, D. A., et al. (2025) · JACC Heart Failure · doi:10.1016/j.jchf.2025.102714 · Cited by 9
Self-citationPediatric Heart Failure Pharmacotherapy: Transformative Insights for the Future
Das, B. B. (2025) · Reviews in Cardiovascular Medicine · doi:10.31083/rcm44109 · Cited by 6
“In the Finerenone in Heart Failure with Preserved Ejection Fraction trial (FINEARTS-HF), finerenone significantly re-7 duced the composite rate of worsening HF events and cardiovascular death in adults with HF with minimal reduction in ejection fraction (HFmEF) compared to placebo [44].”
Heart Failure in the Modern Era: A Narrative Overview of Recent Research from 2022–2025
Wilk, M. M., & Tymków, R. (2025) · Journal of Cardiovascular Development and Disease · doi:10.3390/jcdd12120484 · Cited by 12
“A FINEARTS-HF study of a new member of this group, finerenone, showed that its use in HFmrEF patients led to a reduced risk of cardiovascular death and hospitalization due to HF and cardiovascular death, as well as improved QoL and reduced HF symptoms [106,121].”
Sriperumbuduri, S., Saravanan, P. B., Gupta, G., & Sanyal, A. J. (2025) · Kidney International Reports · doi:10.1016/j.ekir.2025.103757 · Cited by 12
Chronic kidney disease-associated cardiomyopathy: clinical features, pathophysiology and treatment
Edwards, N. C., Pavlovic, D., Ferro, C. J., & Townend, J. (2026) · Nature Reviews Cardiology · doi:10.1038/s41569-025-01234-y · Cited by 8
“165,166).”
Gao, L., Zhang, G., Kang, K., Xu, L., Zhang, W., Chi, C., Zhu, E., Sheheryar, T., Lv, B., & Baodong, X. (2026) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2026.113116 · Cited by 7
Aldosterone and the Mineralocorticoid Receptor in Atrial Fibrillation
Mamazhakypov, A., Peyronnet, R., & Lother, A. (2026) · Hypertension · doi:10.1161/hypertensionaha.125.26187 · Cited by 7
Spetko, N., Scott, C. H., Angell-James, C. E. M., Cassidy, M. A., Alwani, T., Mukherjee, M., Nagueh, S. F., & Strom, J. B. (2026) · Journal of the American Society of Echocardiography · doi:10.1016/j.echo.2026.01.006 · Cited by 6
Aficamten for Symptomatic Nonobstructive Hypertrophic Cardiomyopathy
Masri, A., Maron, M. S., Bhatia, A., Peña‐Peña, M. L., Sherrid, M. V., Figueiredo, E. L., Arad, M., Barriales-Villa, R., Choudhury, L., Claggett, B. L., et al. (2026) · New England Journal of Medicine · doi:10.1056/nejmoa2603021 · Cited by 14
Self-citationEffect of Finerenone in Cardiovascular and Renal Outcomes: A Systematic Review and Meta-analysis
Rivera-Martinez, J. C., Sabina, M., Khanani, A., Lurie, A., Rigdon, A., Abusnina, W. A., Rosado, L. D. L., Bizanti, A., & Paul, T. K. (2025) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-024-07666-x · Cited by 9
“For death from any cause and renal failure, we employed a dichotomous random effects model, reporting outcomes as risk ratios (RR) because the FINEARTS-HF study did not provide HRs for these outcomes [13].”
InfluentialRosano, G. M. C., Teerlink, J. R., Kinugawa, K., Bayés‐Genís, A., Chioncel, O. D., Fang, J. C.-T., Greenberg, B., Ibrahim, N. E., Imamura, T., Inomata, T., et al. (2025) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2025.03.014 · Cited by 10
Self-citationFINEARTS-HF — The Latest Masterpiece for MRAs in Heart Failure
McDonagh, T. A. (2024) · New England Journal of Medicine · doi:10.1056/nejme2411214 · Cited by 6
Cunningham, J. W., & Lam, C. S. P. (2025) · Med · doi:10.1016/j.medj.2025.100772 · Cited by 6
Self-citationKim, S.-E., & Yoo, B. (2025) · The Korean Journal of Internal Medicine · doi:10.3904/kjim.2024.387 · Cited by 5
Advances in Clinical Cardiology 2024: A Summary of Key Clinical Trials
Savage, P., Campbell, M., Hogg, M., McElhatton, D., & Menown, I. B. A. (2025) · Advances in Therapy · doi:10.1007/s12325-025-03220-9 · Cited by 5
“…(rate ratio, 0.84; 95% CI 0.74–0.95; p = 0.007) driven primarily by heart failure events, defined as a first or recurrent unplanned hospitalisation or urgent visit for HF (rate ratio, 0.82; 95% CI 0.71–0.94; p = 0.006) with no significant difference in CV mortality (HR 0.93; 95% CI 0.78–1.11) [80].”
InfluentialPrognosis After >50% Decline in eGFR in Heart Failure Patients
Zahir, D., Elmegaard, M., Garred, C. H., Nouhravesh, N., Fosbøl, E. L., Jhund, P. S., McMurray, J. J. V., Petrie, M. C., Køber, L., & Schou, M. (2025) · JACC Heart Failure · doi:10.1016/j.jchf.2025.02.027 · Cited by 5
Self-citationDecotto, S., Villar, G. M. F., Rossi, E., Iroulart, J. M., Bergier, M. G., Castillo, S. D., de Arenaza, D. P., Lillo, E., Bluro, I. M., Falconi, M. L., et al. (2025) · Current Problems in Cardiology · doi:10.1016/j.cpcardiol.2025.103126 · Cited by 6
Liew, A., Bavanandan, S., Hao, C., Lim, S. K., Prasad, N., Sahay, M., Susantitaphong, P., Roberts, V., Wijewickrama, E. S., Wong, M. G., et al. (2025) · Nephrology · doi:10.1111/nep.70030 · Cited by 7
Carlino, I., Pirrotta, F., Gennari, L., & Palazzuoli, A. (2025) · Biomedicines · doi:10.3390/biomedicines13071693 · Cited by 6
“Finerenone is now viewed as a valuable addition to the therapeutic arsenal across the HF spectrum, including HFrEF, HFmrEF, and HFpEF [5,39].”
Gries, J. J., Chen, B., Bansal, M. B., Rodríguez, M., Alqahtani, S. A., Brennan, P., Lang, C. C., Tang, W. H. W., Lazarus, J. V., & Krittanawong, C. (2025) · Communications Medicine · doi:10.1038/s43856-025-00951-2 · Cited by 8
Reframing cirrhotic cardiomyopathy: a cardiologist’s perspective on an overlooked HFpEF phenotype
Meyer, P., Lu, H. Y., & Solomon, S. D. (2025) · European Heart Journal · doi:10.1093/eurheartj/ehaf545 · Cited by 5
Self-citationSkaarup, K. G., Johansen, N. D., Modin, D., Loiacono, M. M., Harris, R. C., Dufournet, M., Larsen, C. S., Larsen, L., Wiese, L., Dalager‐Pedersen, M., et al. (2025) · Circulation Heart Failure · doi:10.1161/circheartfailure.125.013678 · Cited by 7
Self-citationWu, J., Biswas, D., Brown, S., Ryan, M., Bernstein, B. S., To, B. T., Searle, T., Rizvi, M., Fairhurst, N., Kaye, G., et al. (2025) · European Heart Journal - Digital Health · doi:10.1093/ehjdh/ztaf107 · Cited by 8
Cardiovascular disease epidemiology and management in the elderly and very elderly
Galati, G., Андреевна, Г. О., Dacquino, G. M., Bravo, F. F., Genovese, L., & Pedretti, R. F. E. (2025) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwaf470 · Cited by 7
Cardiac Amyloidosis: Tribulations and New Frontiers
Nguyen, D., Ramazani, N., Sodhi, G., & Tak, T. (2025) · Journal of Personalized Medicine · doi:10.3390/jpm15100472 · Cited by 6
“Other traditional GDMT, such as ARB, ARNI, and beta blockers should be used with caution in this patient population due to risk of hypotension; extra caution should be taken for the patients with autonomic dysfunction [59,103].”
Therapy Gaps for Patients with Heart Failure and Reduced Kidney Function: A Prospective Cohort Study
Ma, C.-H., Qi, A. A., Gagnon, L. R., Wang, K., Sadasivan, C., Ghimire, A., Cooper, M. A., Tungsanga, S., Oguaju, B., Vandermeer, B., et al. (2025) · ESC Heart Failure · doi:10.1002/ehf2.70008 · Cited by 5
“26,27 This represents another area in which emerging therapies can improve care in patients with comorbid HF and kidney dysfunction.”
Merolla, A., Valente, V., Basile, C., Benson, L., Cosentino, F., Dahlström, U., Guðbjörnsdóttir, S., Rovere, P. Q., Lund, L. H., Savarese, G., et al. (2025) · Cardiovascular Diabetology · doi:10.1186/s12933-025-02998-w · Cited by 5
“Recently, the non-steroidal mineralocorticoid receptor agonist finerenone, which had already been shown to reduce the risk of car-diorenal outcomes in patients with T2D, demonstrated a benefit on HF-related outcomes in patients with HFmrEF and HFpEF [11, 38].”
Wang, T.-Y., Zhang, L., Wang, H.-Y., & Jiang, F. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1725782 · Cited by 7
Cheng, D., Hu, J., Zhao, M., Cai, S.-S., Liu, Y., Ge, L., & Cheng, X. (2026) · Scientific Reports · doi:10.1038/s41598-026-35519-0 · Cited by 6
Morikawa, K., Arima, Y., Nagakura, T., Xu, Y., Fujiyama, A., Kataoka, M., Hanatani, S., Matsuzawa, Y., Izumiya, Y., Yamamoto, E., et al. (2026) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2026.153332 · Cited by 6
Chen, S.-H., Tseng, Y., Huang, C., Yang, S., Fudim, M., Chuang, S., Sung, S., & Cheng, H.-M. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70503 · Cited by 6
“47 Unlike spironolactone, which showed inconsistent benefits in HFpEF (e.g., regional heterogeneity in TOPCAT), 48 finerenone demonstrated favourable effects on KCCQ scores and natriuretic peptide levels, particularly in obesity-or metabolism-related phenotypes.”
Emerging Medical Therapies for Primary Aldosteronism
Vibhatavata, P., & Turcu, A. F. (2026) · Hypertension · doi:10.1161/hypertensionaha.126.26229 · Cited by 5
Cardio-Renal Syndrome: Review and New Perspectives
Martín, M., Fernández, M., Bacigalupe, L. P., & Rozado, J. (2026) · Journal of CardioRenal Medicine · doi:10.3390/jcrm2010004 · Cited by 7
Heart failure evidence update 2026
Liori, S., Kapelios, C. J., Savarese, G., & Filippatos, G. S. (2026) · Heart Failure Reviews · doi:10.1007/s10741-026-10609-3 · Cited by 10
Self-citationThomas, J., Dagan, M., Wang, B. H., Gutman, S., & Kaye, D. M. (2026) · Circulation Heart Failure · doi:10.1161/circheartfailure.125.013279 · Cited by 10
Sex differences in cardiovascular–kidney–metabolic syndrome: the FINE-HEART pooled analysis
Pabón, M. A., Ostrominski, J. W., Wang, X., Claggett, B. L., Lo, K. B., Filippatos, G. S., Desai, A. S., Jhund, P. S., Henderson, A., Lam, C. S. P., et al. (2026) · European Heart Journal · doi:10.1093/eurheartj/ehag162 · Cited by 10
Self-citationExcess and Dysfunctional Fat as a Primary Driver of Heart Failure With Preserved Ejection Fraction
Packer, M., Ho, J. E., Petrie, M. C., Schiattarella, G. G., Butler, J., Lam, C. S. P., Vaduganathan, M., Zannad, F. M., & Borlaug, B. A. (2026) · JACC Heart Failure · doi:10.1016/j.jchf.2026.103046 · Cited by 10
Self-citationKubica, J., Kubica, A., Ratajczak, J. M., Gajda, R., Szarpak, Ł., & Navarese, E. P. (2026) · Journal of Clinical Medicine · doi:10.3390/jcm15093486 · Cited by 6
“The FINEARTS-HF trial extended finerenone into this setting by demonstrating a significant reduction in the composite of total worsening heart failure events and cardiovascular death, an effect driven mainly by fewer worsening heart failure events [20].”
InfluentialCVOT Summit Report 2025: advances along the cardiovascular–kidney–metabolic disease continuum
Schnell, O., Agarwal, A., Azizi, M., Ballwieser, D. A., Barnard-Kelly, K. D., Battelino, T., Blüher, M., Bugianesi, E., Cebrián, A., Ceriello, A., et al. (2026) · Cardiovascular Diabetology · doi:10.1186/s12933-026-03140-0 · Cited by 6
“In 2024, the FINEARTS-HF trial demonstrated that the nsMRA finerenone reduced total HF events and cardiovascular death in patients with HFpEF, expanding the range of pharmacological therapies that improve outcomes across the HF spectrum [103, 104].”
Self-citationOptimal serum potassium concentrations in heart failure: an individual patient data meta-analysis
Ono, R., Chimura, M., Docherty, K. F., Henderson, A. D., Campbell, R. T., Desai, A. S., Komajda, M., Packer, M., Pfeffer, M. A., Pitt, B., et al. (2026) · European Heart Journal · doi:10.1093/eurheartj/ehag341 · Cited by 9
Self-citationMineralocorticoid Receptor Antagonists in Myocardial Infarction Patients
d’Entremont, M.-A., Cheema, Z., Pitt, B., Kedev, S., Cornel, J. H., Stankovic, G. R., Moreno, R., Storey, R. F., Bossard, M., Chauhan, A., et al. (2025) · JACC Heart Failure · doi:10.1016/j.jchf.2025.102531 · Cited by 5
Self-citationPark, D., Fuge, J., Kamp, J. C., Harrigfeld, B., Berliner, D., Hoeper, M. M., & Olsson, K. M. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13247582 · Cited by 7
A Saudi Heart Association Position Statement on Cardiovascular Diseases and Diabetes Mellitus
AlHabeeb, W., Elasfar, A., Kinsara, A. J., Aljizeeri, A. H., Jelaidan, I., Alghalayini, K. W., AlKheraiji., M. F., Akbar, M. A. J., Lawand, S., Alyousif, S. M., et al. (2024) · Journal of the Saudi Heart Association · doi:10.37616/2212-5043.1407 · Cited by 11
“The recent FINEARTS-HF trial demonstrated the cardiorenal bene fi t of fi nerenone in HF patients with mildly reduced or preserved ejection fraction, with pre-de fi ned subgroup analyses showing that this bene fi t persists in patients with DM or CKD [208].”
Biglari, S., Mischak, H., Beige, J., Latosińska, A., Siwy, J., & Banasik, M. (2025) · Biomolecules · doi:10.3390/biom15060809 · Cited by 10
Finerenone as a Nonsteroidal Mineralocorticoid Receptor Antagonist for Lupus Nephritis
Sun, M., Xiao, F., Xue, C., Wang, L., & Dai, H. (2025) · Kidney International Reports · doi:10.1016/j.ekir.2025.07.039 · Cited by 4
Coronary Artery Disease in Heart Failure With Preserved Ejection Fraction
Ono, R., & Falcão, L. M. (2025) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2025.08.035 · Cited by 4
Bharaj, I. S., Purewal, K., Munaim, J., Brar, A. S., Kacheria, A., Simister, A., Thirupathy, U., Gupta, P., Kahlon, J., Thwe, E. E., et al. (2025) · Biomedicines · doi:10.3390/biomedicines13092192 · Cited by 7
“The FINEARTS-HF trial demonstrated a significant reduction in the composite outcome of total worsening heart failure events and cardiovascular death (rate ratio 0.84; 95% CI, 0.74–0.95; p = 0.007) over a median follow-up of 32 months [66,67].”
InfluentialHellenkamp, K., Kaebe, S., Valentová, M., von Haehling, S., Delistefani, F., Gollisch, K. S. C., Raddatz, D., Schäfer, A.-K. C., Koziolek, M. J., & Wallbach, M. (2025) · ESC Heart Failure · doi:10.1002/ehf2.15424 · Cited by 6
“11 Accordingly, only fi ve patients (16.1”
InfluentialĆirović, A. (2025) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2025.106882 · Cited by 4
Diallo, A., Carlos‐Bolumbu, M., Duc, P., & Galtier, F. (2025) · EClinicalMedicine · doi:10.1016/j.eclinm.2025.103506 · Cited by 4
“25 Unlike previous meta-analyses, we have included these new important findings, which is crucial for both clinical decisions making and practice guidelines.”
InfluentialCausland, F. R. M., Chatur, S., Vaduganathan, M., Claggett, B. L., Kulac, I. J., Desai, A. S., Jhund, P. S., Henderson, A. D., Rohwedder, K., Amarante, F., et al. (2025) · JACC Heart Failure · doi:10.1016/j.jchf.2025.102778 · Cited by 4
Self-citationRenal protection in heart failure with reduced ejection fraction: not all that glitters is gold
Russo, E., Venturelli, E., Leoncini, G., Viazzi, F. C., & Pontremoli, R. (2025) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2025.106627 · Cited by 7
Efficacy and Safety of the Kidney Function–Based Finerenone Dosing Strategy Used in FINEARTS-HF
Chimura, M., Henderson, A. D., Jhund, P. S., Claggett, B. L., Desai, A. S., Filippatos, G. S., Gajos, G., BRINKER, M. D., Amarante, F., Lay‐Flurrie, J., et al. (2026) · JACC Heart Failure · doi:10.1016/j.jchf.2026.102938 · Cited by 5
Self-citationCardiac involvement in systemic sclerosis: mechanisms, manifestations and management
Soo, C. Y., Jex, N., Bissell, L.-A., Galdo, F. D., & Plein, S. (2026) · Rheumatology · doi:10.1093/rheumatology/keag064 · Cited by 6
Hamatani, Y., Claggett, B. L., Kulac, I. J., Desai, A. S., Jhund, P. S., Henderson, A. D., Lam, C. S. P., Senni, M., Shah, S. J., Voors, A. A., et al. (2026) · European Journal of Heart Failure · doi:10.1093/ejhf/xuag030 · Cited by 5
“11 In brief, the FINEARTS-HF trial was a global, multicentre, parallel-group, double-blind, randomized clinical trial comparing finerenone with a matching placebo in patients with HF and left ventricular ejection fraction (LVEF) of 40% or greater.”
InfluentialSelf-citationRahman, A., Sawano, T., Kitada, K., Jahan, N., Fujisawa, Y., Yamakawa, K., Rahman, M. M., Ye, J., KABIR, M. E., Kadota, K., et al. (2026) · Journal of the American Heart Association · doi:10.1161/jaha.125.044798 · Cited by 5
“8,9 Despite compelling clinical evidence, the fundamental mechanisms underlying cardioprotective effects of fi-nerenone remain incompletely characterized.”
Bagattoli, V., dos Santos, H. S., Giorgi, J. M., Batista, P. K. A., Lopes, S. C., Gambetta, M. V., & Bacca, C. D. O. F. (2026) · European Journal of Heart Failure · doi:10.1093/ejhf/xuag083 · Cited by 5
Cherney, D. Z. I., Alicic, R. Z., & Bonaca, M. P. (2026) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2026.01.010 · Cited by 7
Severe obesity in human HFpEF alters contractile protein function and organization
Jani, V., Rhodehamel, M., Fenwick, A. J., Ma, W., Fisher, E., Giannakopoulos, M. T., Moon, S., Castillo, R. L., Kennedy, L., Irving, T. C., et al. (2026) · Science · doi:10.1126/science.adz7118 · Cited by 13
Self-citationSex differences in pharmacological treatment of heart failure: a meta-analysis of randomized trials
van der Bijl, M. F., Scholte, N. T. B., van Oortmerssen, J. A. E., van Lennep, J. E. R., Schut, A., Westendorp, I. C. D., van der Boon, R. M. A., Brugts, J. J., Kardys, I., Appelman, Y., et al. (2026) · European Heart Journal · doi:10.1093/eurheartj/ehag311 · Cited by 7
Finerenone improves outcomes in HFmrEF and HFpEF
Fernández-Ruíz, I. (2024) · Nature Reviews Cardiology · doi:10.1038/s41569-024-01087-x · Cited by 4
Hellenkamp, K., Sato, R., & von Haehling, S. (2025) · Med · doi:10.1016/j.medj.2024.12.004 · Cited by 4
Pliças, M. M. D., da Silva, B. M., & Almeida, E. (2025) · Nefrología (English Edition) · doi:10.1016/j.nefroe.2025.02.010 · Cited by 3
Adverse effects of finerenone in patients with heart failure: a systematic review and meta-analysis
Yu, W., Luo, F., Rao, J., Lei, G., Wu, Q., Shen, W., Yang, P., & Li, P. (2025) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2025.1601552 · Cited by 7
Decongestion in patients with advanced chronic kidney disease coexisting with heart failure
Zoccali, C., Levin, A., Mallamaci, F., Giugliano, R. P., & Caterina, R. D. (2025) · Clinical Kidney Journal · doi:10.1093/ckj/sfaf185 · Cited by 6
“Finerenone improved the risk for worsening HF and death from cardiovascular causes in patients with mildly reduced or preserved ejection fraction ( EF) [22 ].”
Sadlonova, M., Celano, C. M., Huffman, J. C., Jetzke, M., Derad, C., Broschmann, D., Feuerstein, A., Hasenfuss, G. P., Nolte, K., Pieske, B. M., et al. (2025) · Journal of Psychosomatic Research · doi:10.1016/j.jpsychores.2025.112344 · Cited by 5
Aldosterone and Cardiovascular Risk Across the Lifespan
Ananda, R. A., Mori, T. A., & Yang, J. (2025) · Metabolites · doi:10.3390/metabo15080553 · Cited by 5
“Current evidence supports the benefits of targeted PA treatment, even when the initial LV function is preserved [92], especially with unsuppressed renin, but its therapeutic role in overt HFrEF remains unknown and require further evaluation.”
Hyperkalemia in Heart Failure with Reduced Ejection Fraction: Implications and Management
Beavers, C. J., & Greene, S. J. (2025) · Heart Failure Reviews · doi:10.1007/s10741-025-10549-4 · Cited by 10
New Fuels for a Failing Engine: The Impact of Novel Heart Failure Drugs on Functional Capacity
Baracchini, N., Capovilla, T. M., Costantino, S., Puttini, F., Salvioni, E., Mattavelli, I., Valenti, M., d'Elia, E., Bertarelli, E., Agostoni, P., et al. (2025) · Reviews in Cardiovascular Medicine · doi:10.31083/rcm41919 · Cited by 5
“In contrast to SGLT2 inhibitors, finerenone has demonstrated no documented impact on CPET-derived parameters in HFpEF [61].”
The Role of the Left Atrium in the Pathogenesis of Heart Failure With Preserved Ejection Fraction
Ovchinnikov, A. G., Potekhina, A. V., Filatova, A. Y., Николаевна, С. О., Shogenova, M., Sobolevskaya, M. S., & Ageev, F. T. (2024) · Kardiologiia · doi:10.18087/cardio.2024.11.n2799 · Cited by 4
Platz, E., McDowell, K., Gupta, D. K., Claggett, B. L., BRENNAN, A., Charles, L. J., Cunningham, J. W., Dixon, D., Docherty, K. F., Jering, K., et al. (2025) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2025.02.013 · Cited by 4
Self-citationSezai, A., Abe, M., Maruyama, T., Taoka, M., Sekino, H., & Tanaka, M. (2025) · Life · doi:10.3390/life15050741 · Cited by 9
“…a large-scale study (FINEARTS-HF trial) of finerenone, a non-steroidal MRA similar to esaxerenone, conducted in patients with HFmrEF and HFpEF, finerenone significantly reduced the composite incidence of total events due to worsening heart failure and cardiovascular death compared to placebo [38].”
Use of finerenone in patients with chronic kidney disease at high risk of heart failure
Hakim, J. P., Handelsman, Y., & Banerjee, T. (2025) · Metabolism · doi:10.1016/j.metabol.2025.156297 · Cited by 5
Finerenone’s Promise in Heart Failure and Kidney Disease
Shokri, K., Mohammadi, A., Karimian, A., Adeel, M. Y., Mozaffari, M. A., Frishman, W. H., & Aronow, W. S. (2025) · Cardiology in Review · doi:10.1097/crd.0000000000000958 · Cited by 6
Oswald, T., Coombs, S., Ellery, S. M., & Liu, A. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14113948 · Cited by 7
“Recent data has demonstrated that Finerenone, unlike other steroidal MRAs (Spironolactone or Eplerenone), when given to patients with an LVEF of 40% or greater reduced the risk of total HF events and causes of death related to CVD when compared to placebo [8].”
MRAs, SGLT2 Inhibitors, and Kidney Outcomes in CKD and HF
Mendonça, L., Neves, J. S., Testani, J., Zannad, F. M., & Ferreira, J. P. (2025) · JACC Heart Failure · doi:10.1016/j.jchf.2025.102514 · Cited by 6
Self-citationCotter, G., Davison, B. A., Biegus, J., Pagnesi, M., Metra, M., Butler, J., Chioncel, O. D., Ponikowski, P. P., & Mebazaa, A. (2025) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2024.12.015 · Cited by 3
Self-citationAgrawal, S. P., Tated, R. C. P., Maheta, D., & Aronow, W. S. (2025) · Minerva Medica · doi:10.23736/s0026-4806.25.09656-9 · Cited by 5
Haq, N., Uppal, P., Abedin, T., & Lala, A. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14093213 · Cited by 7
Halimi, J., Fauchier, L., Karras, A., Amouyal, C., Eladari, D., Rossignol, P., Choukroun, G. J., Zaoui, P., Girerd, N., & Hadjadj, S. (2025) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwaf426 · Cited by 9
An approach to the older patient with a suspicion of HFpEF
Gelfman, D. M. (2025) · The American Journal of Medicine · doi:10.1016/j.amjmed.2025.07.036 · Cited by 3
Kobayashi, M., Duarte, K., Ferreira, J. P., Baudry, G., Monzo, L., McMurray, J. J. V., van Veldhuisen, D. J., Pitt, B., Zannad, F. M., & Girerd, N. (2025) · European Journal of Heart Failure · doi:10.1002/ejhf.70047 · Cited by 3
Self-citationAdvances in Pharmacotherapies for Obesity-Related HFpEF: A Comprehensive Review
Wu, Y., Song, M., Chen, X., Chen, W., Wu, M., & Lin, L. (2025) · Current Heart Failure Reports · doi:10.1007/s11897-025-00722-z · Cited by 3
“Treatment with finerenone led to a statistically significant reduction in the composite endpoint of total worsening heart failure events and cardiovascular mortality compared to placebo [ 67].”
Myte, R., Mattsson, A., Poole, M., Little, D. J., Nyström, P. O., Henderson, A. D., Claggett, B. L., Gasparyan, S. B., Solomon, S. D., & McMurray, J. J. V. (2025) · Circulation Heart Failure · doi:10.1161/circheartfailure.125.013496 · Cited by 5
Self-citationOstrominski, J. W., Neuen, B. L., Claggett, B. L., Filippatos, G. S., Desai, A. S., Jhund, P. S., Henderson, A. D., Lam, C. S. P., Senni, M., Shah, S. J., et al. (2025) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2025.10.060 · Cited by 3
Self-citationPozzi, A., Spoladore, R., Iorio, A., Corrado, G., & D’Amario, D. (2025) · Heart Failure Reviews · doi:10.1007/s10741-025-10585-0 · Cited by 5
Meyer, P., Rocca, A., Banús, J., Ogier, A. C. C., Georgantas, C., Calarnou, P., Fatima, A., Vallée, J., Deux, J., Thomas, A., et al. (2025) · Journal of the American Heart Association · doi:10.1161/jaha.125.043541 · Cited by 5
“13 Although SGLT2 (sodium-glucose cotransporter-2) inhibitors and the mineralocorticoid receptor antagonist finerenone have shown promise in HF with mildly reduced EF and HFpEF, 14–16 no trial has yet demonstrated a significant reduction in overall or cardiovascular mortality in HFpEF.”
Causland, F. R. M., Heerspink, H. J. L., Vaduganathan, M., Claggett, B. L., Desai, A. S., Jhund, P. S., McGrath, M. M., Rohwedder, K., Amarante, F., BRINKER, M. D., et al. (2025) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.0000000849 · Cited by 4
Self-citationConsensus Statement on Optimisation of Patient Care After Hospitalisation for Acute Heart Failure
Sindone, A. P., Amerena, J. V., Pasquale, C. G. D., Chan, A., Gan, G. C. H., RAO, S. D., Burdeniuk, C., Shah, A. M., & Atherton, J. J. (2026) · Heart Lung and Circulation · doi:10.1016/j.hlc.2025.09.019 · Cited by 4
Self-citationButt, J. H., Henderson, A. D., Jhund, P. S., Claggett, B. L., Desai, A. S., Borentain, M., Rohwedder, K., Dayoub, R., Sanctis, Y. D., Lam, C. S. P., et al. (2026) · Circulation Heart Failure · doi:10.1161/circheartfailure.125.013201 · Cited by 3
Self-citationAlmas, T., Shelig, M., Al-Hindawi, A., Bansal, K., Akbar, A., Qureshi, A. N., Ismayl, M., Reed, J. A., Burahmah, J., Alhamlan, A. W., et al. (2026) · European Heart Journal - Quality of Care and Clinical Outcomes · doi:10.1093/ehjqcco/qcag014 · Cited by 5
Diabetic Kidney Disease: From Pathophysiology to Treatment Perspectives
Varda, L., Vreča, N., Ekart, R., Bevc, S., & Piko, N. (2026) · Kidney & Blood Pressure Research · doi:10.1159/000550085 · Cited by 15
Kramer, H. J., & Bakris, G. L. (2026) · Journal of Internal Medicine · doi:10.1111/joim.70066 · Cited by 4
“Finerenone recently received an HF indication by the FDA (2025) to reduce the risk of cardiovascular death, hospitalization for HF, and urgent HF visits in adult patients with HF with an LVEF ≥ 40% [128] based on the results of the FINEARTS-HF trial [146].”
Established and emerging pharmacologic options and unmet needs in HFpEF and HFmrEF
Sauer, A. J., ter Maaten, J. M., & Savarese, G. (2026) · ESC Heart Failure · doi:10.1093/eschf/xvag056 · Cited by 5
Metadata
- Authors
- Solomon, S. D., McMurray, J. J. V., Vaduganathan, M., Claggett, B., Jhund, P. S., Desai, A. S., Henderson, A. D., Lam, C. S. P., Pitt, B., Senni, M., Shah, S. J., Voors, A. A., Zannad, F., Abidin, I. Z., Alcocer-Gamba, M. A., Atherton, J. J., Bauersachs, J., Chang-Sheng, M., Chiang, C.-E., Chioncel, O., Chopra, V., Comin-Colet, J., Filippatos, G., Fonseca, C., Gajos, G., Goland, S., Goncalvesova, E., Kang, S., Katova, T., Kosiborod, M. N., Latkovskis, G., Lee, A. P.-W., Linssen, G. C. M., Llamas-Esperón, G., Mareev, V., Martinez, F. A., Melenovský, V., Merkely, B., Nodari, S., Petrie, M. C., Saldarriaga, C. I., Saraiva, J. F. K., Sato, N., Schou, M., Sharma, K., Troughton, R., Udell, J. A., Ukkonen, H., Vardeny, O., Verma, S., von Lewinski, D., Voronkov, L., Yilmaz, M. B., Zieroth, S., Lay-Flurrie, J., van Gameren, I., Amarante, F., Kolkhof, P., & Viswanathan, P.
- Affiliations
- Brigham and Women's Hospital (US)
- From the Cardiovascular Division, Brigham and Women’s Hospital, and Harvard Medical School, Boston (S.D.S., M.V., B.C., A.S.D.); British Heart Foundation Cardiovascular Research Centre, School of Cardiovascular and Metabolic Health, University of Glasgow, Glasgow (J.J.V.M., P.S.J., A.D.H., M.C.P.), and Bayer, Reading (J.L.-F.) — both in the United Kingdom; National Heart Centre Singapore and Duke–National University of Singapore, Singapore (C.S.P.L.); University of Michigan School of Medicine, Ann Arbor (B.P.); University of Milano-Bicocca and Papa Giovanni XXIII Hospital, Bergamo (M. Senni), and the Department of Cardiology, University of Brescia, and ASST “Spedali Civili” Hospital, Brescia (S.N.) — all in Italy; Northwestern University Feinberg School of Medicine, Chicago (S.J.S.); University Medical Center Groningen, Groningen (A.A.V.), the Department of Cardiology, Hospital Group Twente, Almelo (G.C.M.L.), and Bayer, Hoofddorp (I.G.) — all in the Netherlands; Université de Lorraine, INSERM Clinical Inv...
- ORCID
- Solomon, Scott D.
- McMurray, John J.V.
- Vaduganathan, Muthiah
- Claggett, Brian
- Jhund, Pardeep S.
- Desai, Akshay S.
- Henderson, Alasdair D.
- Lam, Carolyn S.P.
- Pitt, Bertram
- Senni, Michele
- Shah, Sanjiv J.
- Voors, Adriaan A.
- Zannad, Faiez
- Abidin, Imran Zainal
- Alcocer-Gamba, Marco Antonio
- Atherton, John J.
- Bauersachs, Johann
- Chiang, Chern-En
- Chioncel, Ovidiu
- Chopra, Vijay
- Filippatos, Gerasimos
- Fonseca, Cândida
- Gajos, Grzegorz
- Goland, Sorel
- Kosiborod, Mikhail N.
- Latkovskis, Gustavs
- Lee, Alex Pui-Wai
- Linssen, Gerard C.M.
- Melenovský, Vojtěch
- Merkely, Béla
- Nodari, Savina
- Petrie, Mark C.
- Saldarriaga, Clara Inés
- Saraiva, Jose Francisco Kerr
- Sato, Naoki
- Schou, Morten
- Troughton, Richard
- Udell, Jacob A.
- Ukkonen, Heikki
- Vardeny, Orly
- Verma, Subodh
- von Lewinski, Dirk
- Voronkov, Leonid
- Zieroth, Shelley
- Kolkhof, Peter
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2024-10-24
- Volume
- 391
- Issue
- 16
- Pages
- 1475-1485
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W4402101139
- Cited by
- 893
- References
- 21
- Citations by year
- 2026: 414 · 2025: 398 · 2024: 81
- FWCI
- 268.66
- Type
- journal article
- Language
- en
- Open access
- green
- hal.univ-lorraine.fr
- Licence
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- HAL (submittedVersion, other-oa)
- Jagiellonian University Repository (Jagiellonian University) (submittedVersion, cc-by-nc-nd)
- BOA (University of Milano-Bicocca) (submittedVersion)
- Institutional Research Information System (Università degli Studi di Brescia) (submittedVersion, other-oa)
- University of Groningen research database (University of Groningen / Centre for Information Technology) (submittedVersion, other-oa)
- Funders
- Bayer
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Hormonal Regulation and Hypertension
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiac Fibrosis and Remodeling
- Keywords
- finerenone, heart failure with mildly reduced ejection fraction, heart failure with preserved ejection fraction, mineralocorticoid receptor antagonists, non-steroidal mineralocorticoid receptor antagonists, cardiovascular mortality, hyperkalemia, hypokalemia, FINEARTS-HF trial, left ventricular ejection fraction, heart failure hospitalization, drug safety
- MeSH terms
- Aged, Aged, 80 and over, Mineralocorticoid Receptor Antagonists, Double-Blind Method, Female, Follow-Up Studies, Heart Failure, Hospitalization, Humans, Male, Middle Aged, Naphthyridines, Stroke Volume, Treatment Outcome, Kaplan-Meier Estimate
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.